Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantinos G. Kyriakoulis has a total of 271 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    May Measurement Month 2023: Implementation of a global opportunistic blood pressure screening campaign in Greece

    by Ariadni Menti, Anastasios Kollias, Haralampos Milionis, Angelos Liontos, Eugenia Gkaliagkousi, Vasileios Kotsis, Christos Savopoulos, Areti Triantafyllou, Ioannis Zarifis, Spyridon Maragkoudakis, et al.

    The May Measurement Month (MMM) 2023 global blood pressure (BP) screening campaign was conducted in Greece aiming to raise hypertension awareness and control in the general population. Volunteers aged ≥18 years were recruited through opportunistic screening in 11 cities. Each participant was assessed with triplicate seated BP measurements using validated automated upper-arm cuff devices and a standardized questionnaire on medical history. These data were submitted online through a custom-designed app of the global MMM campaign. Hypertension was defined as BP ≥140/90mmHg (average of second-third measurement) and/or use of antihypertensive drugs. A total of 5,437 individuals were analysed (mean age 53±17.1 years, 46.2% men, 27.8% current smokers, 10.9% with diabetes, 6.7% with cardiovascular disease) and 41.7% were hypertensive. The prevalence of hypertension was higher in men compared to women and in older compared to youngers individuals. Among hypertensives, 73.9% were unaware of their diagnosis, 69.9% were on antihypertensive drugs, and 47.6% were treated and controlled (BP <140/90mmHg). These data suggest that in Greece a high prevalence of hypertension persists, and often is undiagnosed, untreated, and uncontrolled. Global BP screening campaigns such as MMM are important and need to be complemented by public health initiatives at a national level for improving hypertension diagnosis and control.

  • Single Interventions (Pharmacological or Renal Denervation) Are Not Sufficient to Achieve Blood Pressure Control in Resistant Hypertension a Systematic Review and Meta-Analysis

    by Konstantinos Tsioufis, Konstantinos G. Kyriakoulis, Angeliki Vakka, Nektaria Stamataki, Fotios Tatakis, Dimitrios Konstantinidis, Costantinos Mihas, Stergios Soulaidopoulos, Alexandros Kasiakogias, Athanasios Kordalis, et al.

    BACKGROUND: Resistant hypertension remains a major clinical challenge. This systematic review/meta-analysis evaluated whether the addition of a single pharmacological or device-based intervention (renal denervation [RDN]) can achieve effective blood pressure (BP) control in patients with true resistant hypertension. METHODS: A systematic search of MEDLINE/PubMed was performed to identify studies assessing the antihypertensive effects of adding a single pharmacological or device-based intervention in patients with true resistant hypertension. Primary analyses were conducted using a single-arm framework. RESULTS: Sixty-eight studies were included (n=6297; weighted mean age, 60 years; males 60%; diabetes 35%; smoking 16%; cardiovascular disease 27%). Participants received an average of 4.8 antihypertensive medications, with baseline office BP of 164/92 mm Hg and 24-hour ambulatory BP of 148/85 mm Hg. The median follow-up was 6 months. Meta-analysis of 58 studies (n=4579; 52% RDN) demonstrated a pooled mean 24-hour systolic ambulatory BP reduction from baseline of −11.3 mm Hg (95% CI, −12.3 to −10.2). Meta-analysis of 15 studies (n=2700; 15% RDN) showed a pooled hypertension control rate during follow-up of 35% (95% CI, 28–42). No significant differences were observed between RDN and pharmacotherapy or between randomized and nonrandomized studies. CONCLUSIONS: A single intervention—either pharmacological or RDN—on top of guideline-directed background therapy resulted in clinically meaningful BP reduction in patients with true resistant hypertension; however, only one-third of patients achieved BP control. Future clinical trials are needed to evaluate whether combination treatment strategies integrating optimized pharmacological regimens with RDN can provide more effective and durable BP control in this particularly challenging patient population.


  • Open Access

    Routine Handheld Carotid Ultrasonography for Cardiovascular Risk Stratification and Primary Prevention Treatment Decisions in a Contemporary Middle‐Aged General Population

    by Anastasios Kollias, Aikaterini Komnianou, Konstantinos G. Kyriakoulis, Ariadni Menti, Dimitrios Mariglis, Eirini‐Chrysovalanti Antonogiannaki, Thomas Tsaganos, George S. Stergiou


  • Open Access

    SCORE2 versus HellenicSCORE II+ algorithms in detecting preclinical carotid atherosclerosis in a middle-aged general population sample in Greece

    by Anastasios Kollias, Aikaterini Komnianou, Dimitra Krystallaki, Thomas Tsaganos, Eirini-Chrysovalanti Antonogiannaki, Emelina Stambolliu, Konstantinos G. Kyriakoulis, Ariadni Menti, George S. Stergiou

  • Open Access

    In-Treatment Kinetics of Peripheral Blood Immune Markers in PD-L1 High Non-Small Cell Lung Cancer and Prognostic Relevance for Immunotherapy Outcomes

    by Ioannis P. Trontzas, Ioanna-Evdokia Galani, Emmanouil Panagiotou, Efthymia Theofani, Anastasia Georganta, Konstantinos G. Kyriakoulis, Anastasia Palaiologou, Ioannis Vathiotis, Constantin Tamvakopoulos, Evangelos Andreakos, et al.

    Background: A substantial proportion of patients with non-small cell lung cancer (NSCLC) derive limited clinical benefit from immunotherapy. Monitoring of peripheral blood immune markers (PBIMs) may emerge as a useful tool to predict treatment outcomes with immune checkpoint inhibitors (ICIs). Patients/Methods: We prospectively measured several PBIMs in a PD-L1 high (TPS ≥ 50%) NSCLC cohort of patients treated with first-line pembrolizumab monotherapy. Kinetics over the first year of treatment were assessed at baseline (T0) and at 21 days (T1), 3 months (T2), 6 months (T3) and at 1 year (T4) post-treatment initiation. Associations with clinical outcomes were explored after a 2-year follow-up period. Results: In total, 31 patients with PD-L1 high locally advanced or metastatic NSCLC were prospectively enrolled. Over the first year of treatment, levels of CRP, IL-17α, IL-6, and IL-8 were significantly decreased. Early kinetics analysis showed significant decrease in total leukocytes, neutrophils, CRP, and MIP-3α/CCL20, as well as significant transient elevation of ITAC/CXCL11, IL-1β, IL-7, and TNFα, during the first 3 months of treatment. Early percent changes (Δ% at T1 and at T2) of ‘low’ vs. ‘high’ pretreatment levels showed significant differences for LDH, ITAC/CXCL11, GM-CSF, MIP-1α/CCL3, IL-2, IL-4, IL-5, and sPD-L1. Longitudinal analysis, stratified per responders and for pre-progression fluctuations, did not reveal significant findings. Among markers with acceptable discriminative performance, higher baseline CRP, complement C4, and IL-6 levels were associated with poorer clinical outcomes. In multivariable analysis, only C4 retained independent prognostic significance; however, integration of these PBIMs into composite indices improved prognostic performance. Conclusions: In this prospective study, longitudinal monitoring of PBIMs provided descriptive insights into immune and inflammatory dynamics during pembrolizumab treatment; however, no significant associations were observed between in-treatment biomarker kinetics and clinical outcomes. In exploratory analyses, baseline CRP, complement C4, and IL-6 levels were associated with clinical outcomes, and their integration into composite indices improved prognostic performance. These findings suggest that specific baseline PBIMs may carry prognostic relevance, while the role of in-treatment monitoring remains to be further clarified in larger prospective studies.


  • Pembrolizumab trough concentration monitoring and association with outcomes in advanced non-small cell lung cancer

    by Ioannis P. Trontzas, Anastasia Palaiologou, Natalia Kamperi, Anastasia Georganta, Emmanouil Panagiotou, Ioanna-Maria Orfanou, Konstantinos G. Kyriakoulis, Ioannis Vathiotis, Elias A. Kotteas, Dimitra Grapsa, et al.

    Therapeutic drug monitoring (TDM) of immune checkpoint inhibitors (ICIs) remains limited due to drug-related challenges; however, a better understanding of exposure - effect relationships may improve antitumor activity and reduce immune-related adverse events (irAEs). We conducted a prospective TDM study measuring pembrolizumab trough concentrations (Cmin) using a commercial ELISA kit in 31 patients with advanced non-small cell lung cancer (NSCLC) receiving pembrolizumab monotherapy. Serial Cmin measurements were obtained at baseline (T0), before cycle 2 (T1), and at 3 (T2), 6 (T3), and 12 months (T4). Baseline clinicopathologic and serologic variables were recorded. Patients were followed for two years to assess treatment outcomes. Pembrolizumab Cmin increased significantly over time (p < 0.0001), with the greatest rise after T2 (T1 vs. T2, p < 0.001) and stabilization thereafter (T3 vs. T4, p = 0.25). Higher Cmin levels at later timepoints were associated with improved clinical outcomes. Elevated Cmin correlated with a greater number of organ systems affected by irAEs. High baseline albumin and fewer comorbidities were predictors of higher Cmin. Pembrolizumab TDM is a feasible approach in NSCLC. Higher late-treatment Cmin levels may be associated with favorable outcomes, supporting pembrolizumab exposure as a potential biomarker and highlighting TDM as a tool for dose-tailoring strategies.


  • Favorable Effects of Renal Denervation in Hypertension‐Related Comorbidities. A Systematic Review and Meta‐Analysis

    by Athanasios Makris, Stergios Soulaidopoulos, Marios Sagris, Konstantinos Platanias, Konstantinos Kyriakoulis, Dimitrios Konstantinidis, Fotis Tatakis, Georgios Gompos, Kyriakos Dimitriadis, Athanasios Kordalis, et al.

    Background: Renal denervation (RDN) according to the latest ESH guidelines can be considered as a treatment option for patients with resistant hypertension. However, excess sympathetic nervous system activity constitutes an underlying pathophysiological mechanism in many disorders other than arterial hypertension. Aims: This systematic review and meta‐analysis investigated the therapeutic effects of RDN beyond arterial hypertension. Methods: A systematic review and meta‐analysis were conducted following PRISMA guidelines. Electronic databases (PubMed, Embase, Cochrane) were searched for studies assessing RDN effects in atrial fibrillation (AF) recurrence, obstructive sleep apnea (OSA), metabolic parameters, heart failure (HF) and diastolic heart function. Inclusion criteria encompassed randomized controlled trials and observational studies with relevant outcome measures. Effect sizes were pooled using a random‐effects model. Results: A total of 16 studies comprising 818 patients were included. RDN was associated with a significant increase in freedom from AF when combined with pulmonary vein isolation (RR: 1.30, 95% CI: 1.04 to 1.61, I 2 = 5%), an improvement in OSA severity as measured by the apnea‐hypopnea index (MD: −4.80, 95% CI: −12.60 to 3.01, I 2 = 39%), and decreased fasting blood glucose (MD: −10.04, 95% CI: −26.51 to 6.43, I 2 = 0%). Additionally, RDN led to improvements in left ventricular diastolic function in terms of E/e' reduction (MD: −1.51, 95% CI: −2.71 to −0.31, I 2 = 94%) and improved HF‐related biomarkers, specifically NT pro‐BNP (MD: −438.54, 95% CI: −1658.57 to 781.49, I 2 = 92%) and 6‐min walking distance (MD: +64.58, 95% CI: 0.11 to 129.05, I 2 = 53%). Conclusion: This meta‐analysis suggests that RDN exerts beneficial effects beyond hypertension, particularly in AF burden, OSA severity, metabolic parameters, and cardiac function. These findings support the broader role of RDN in autonomic regulation and cardiovascular health. Further large‐scale trials are warranted to confirm these effects and refine patient selection criteria.


  • CCTA and CACS for preoperative cardiovascular risk stratification in patients undergoing noncardiac surgery: A systematic review and meta-analysis

    by Ioannis Kyriakoulis, Konstantinos G. Kyriakoulis, Konstantinos Aznaouridis, Sriram Sunil Kumar, Dimitrios Schizas, Damianos G. Kokkinidis


  • Top Cited Papers

    Cuffless Blood Pressure Measurement: Where Do We Actually Stand?

    by Ramakrishna Mukkamala, Sanjeev G. Shroff, Konstantinos G. Kyriakoulis, Alberto P. Avolio, George S. Stergiou

    Cuffless blood pressure (BP) measurement offers considerable potential for clinical practice but is a challenging technological field. Many are investigating pulse wave analysis with or without pulse arrival time in which machine learning is applied to pulsatile waveforms obtained with mobile devices (eg, wristbands, smartphones) to estimate BP. These methods generally require individual user calibration with cuff BP measurements or demographics (eg, age, sex). This calibration makes it difficult to evaluate the method’s accuracy, and many studies claiming accuracy used inadequate testing procedures. Yet, publications and regulatory-cleared devices continue to rise, seemingly implying technological advancements. An update is provided on the flurry of activity in cuffless BP technologies over the last 2 to 3 years, covering the clinical need, the latest devices, recent publications based on pulse wave analysis and pulse arrival time, progress in developing validation standards for cuffless BP devices, and recent publications on other cuffless BP measurement principles. Despite the high volume of research and development, to date, there is no compelling evidence that pulse wave analysis and pulse arrival time can provide significant added value in BP measurement accuracy beyond the cuff BP or demographic data for calibration. Thus, it is reasonable to at least be skeptical of published and future studies on pulse wave analysis and pulse arrival time for cuffless BP measurement with uncertain testing procedures. It is important to focus on establishing robust validation standards for cuffless BP devices requiring individual user calibration and also pursuing cuffless and calibration-free BP measurement methodologies going forward.